- Home
- IDXX vs ARGX Comparison
IDXX vs ARGX Comparison
Compare IDXX & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDXX
- ARGX
- Stock Information
- Founded
- IDXX 1983
- ARGX 2008
- Country
- IDXX United States
- ARGX Netherlands
- Employees
- IDXX N/A
- ARGX N/A
- Industry
- IDXX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IDXX Health Care
- ARGX Health Care
- Exchange
- IDXX Nasdaq
- ARGX Nasdaq
- Market Cap
- IDXX 34.1B
- ARGX 40.4B
- IPO Year
- IDXX 1991
- ARGX 2017
- Fundamental
- Price
- IDXX $437.44
- ARGX $614.76
- Analyst Decision
- IDXX Buy
- ARGX Strong Buy
- Analyst Count
- IDXX 8
- ARGX 20
- Target Price
- IDXX $523.75
- ARGX $699.56
- AVG Volume (30 Days)
- IDXX 1.1M
- ARGX 448.6K
- Earning Date
- IDXX 05-01-2025
- ARGX 05-08-2025
- Dividend Yield
- IDXX N/A
- ARGX N/A
- EPS Growth
- IDXX 6.06
- ARGX N/A
- EPS
- IDXX 10.67
- ARGX 12.78
- Revenue
- IDXX $3,897,504,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- IDXX $7.74
- ARGX $60.97
- Revenue Next Year
- IDXX $7.74
- ARGX $31.50
- P/E Ratio
- IDXX $41.00
- ARGX $44.63
- Revenue Growth
- IDXX 6.46
- ARGX 77.22
- 52 Week Low
- IDXX $356.14
- ARGX $352.77
- 52 Week High
- IDXX $548.88
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- IDXX 59.66
- ARGX 57.38
- Support Level
- IDXX $424.48
- ARGX $593.31
- Resistance Level
- IDXX $441.87
- ARGX $604.77
- Average True Range (ATR)
- IDXX 17.95
- ARGX 21.09
- MACD
- IDXX 6.07
- ARGX 5.10
- Stochastic Oscillator
- IDXX 94.83
- ARGX 98.32
About IDXX IDEXX Laboratories Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.